Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 0711 • ACR Convergence 2025
Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation
Natalia Swierczynska¹, Ruaridh Armour¹, Anthony Yau¹, Enn Rusi¹, Mark Hooper¹, Jason Sillitoe², Caroline Wilson², Paula Griffiths³, Tariq El-Shanawany³, Faye Sims⁴, Gerber Gomez⁵, Christian Fischer⁵, Michael Hausmann⁶ and Helen Laird¹, ¹Research & Development, AliveDx, Edinburgh, Scotland, United Kingdom, ²North East Innovation Lab, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ³Immunology Department, Laboratory Medicine, Swansea Bay University Health Board, UK. Cardiff and Vale UHB, Swansea, Wales, United Kingdom, ⁴Clinical Biochemistry and Immunology Department Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, England, United Kingdom, ⁵Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland, ⁶AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA), including those directed to myeloperoxidase (MPO) and proteinase 3 (PR3) as well as antibodies against anti-glomerular basement membrane (anti-GBM) are…
Abstract Number: 2511 • ACR Convergence 2025
The SHIPE index: A tertile-based approach to predict end-stage kidney disease in ANCA-associated vasculitis
HYUNSUE DO¹, Lucy Eunju Lee², Jang Woo Ha³, Jason Jungsik Song⁴, Yong-Beom Park⁵ and Sang-Won Lee⁶, ¹Kangwon national university hospital, Seoul, South Korea, ²Yonsei University, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea, ⁴Yonsei University College of Medicine, Seoul, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁶Yonsei university college of medicine, Seoul, South Korea
Background/Purpose: This study aimed to develop a simple, robust, and ethnoregion-specific index for predicting progression to end-stage kidney disease (ESKD) in Korean patients with antineutrophil…
Abstract Number: 1611 • ACR Convergence 2025
Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study
Yusuke Ushio¹, Hiromi Shimada², Taichi Miyagi³, Koichi Sugihara², Mao Mizusaki², Rina Mino², Kanako Chujo³, Naoto Manabe³, Mayuko Wada², Shusaku Nakashima² and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita District, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Avacopan, an oral C5a receptor antagonist, offers a promising glucocorticoid (GC)-sparing option for patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Although…
Abstract Number: 1594 • ACR Convergence 2025
Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis
Benjamin Terrier¹, David Jayne², Bernhard Hellmich³, Nancy Agmon-Levin⁴, Parameswaran Nair⁵, Lena Börjesson Sjö⁶, Priya Jain⁷, Aadarsh Lal⁸, Sofia Necander⁹, Claire Walton¹⁰, Peter Merkel¹¹ and Michael Wechsler¹², ¹Cochin Hospital, Paris, France, ²University of Cambridge, Cambridge, United Kingdom, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Clinical Immunology, Angioedema and Allergy, Sheba Medical Center, Ramat Gan, Israel, ⁵Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁶Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁸Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ⁹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Department of Medicine, National Jewish Health, Denver
Background/Purpose: The MANDARA trial (NCT04157348) demonstrated that after two years of anti-interleukin-5/receptor (anti-IL-5/R) therapy over 60% of patients with relapsing or refractory eosinophilic granulomatosis with…
Abstract Number: 0633 • ACR Convergence 2025
Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis (AAV) and Systemic Lupus Erythematosus (SLE): A Comparative Analysis
Sai Shanmukha Sreeram Pannala¹, Medha Rajamanuri², Srikar Sama³, Fares Saliba⁴, Omar Mourad⁵, Elizabeth Fagin⁶, Koushik Varma Sangaraju⁷, Veena Katikineni⁸ and Anastasia Slobodnick⁹, ¹Northwell health/Staten Island university Hospital, new york city, NY, ²Southern Illinois University School of Medicine, Springfield, IL, ³University of California San Francisco Fresno, Fresno, CA, ⁴Staten Island University Hospital, Staten Island, NY, ⁵Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, Staten Island, NY, ⁶Staten Island University Hospital, Teaneck, NJ, ⁷St. Luke's University Health Network, Bethlehem, PA, ⁸Desert Orthopaedic and Rheumatologic Institute, Apple Valley, CA, ⁹Northwell, Staten Island, NY
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a rare but severe complication in Systemic Lupus Erythematosus (SLE), occurring in up to one-third of cases at disease…
Abstract Number: 2509 • ACR Convergence 2025
Predicting future relapse with proteomics in ANCA-Associated Vasculitis
Evan Barnes¹, Nora Shepherd², Colebrooke Johnson¹, David O'Dea¹, Bohang Jiang³, Emily Hyle², Zachary Williams⁴, Zachary Wallace⁵ and Gary Reynolds⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³MGH, Boston, MA, ⁴Massachusetts General Hospital, Nancy, KY, ⁵Massachusetts General Hospital, Newton, MA, ⁶Massachusetts General Hospital, Newcastle upon Tyne, United Kingdom
Background/Purpose: Outcomes for ANCA associated vasculitis (AAV) have been transformed in recent years with many patients achieving prolonged periods of remission. Guidelines advise continuing maintenance…
Abstract Number: 1610 • ACR Convergence 2025
Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients
Takashi Yamane¹, Ayaka Inoue², Noriaki Yasuda², Takahisa Ohnishi³ and Akira Hashiramoto⁴, ¹Kakogawa Central City Hospital, Kobe, Hyogo, Japan, ²Kakogawa Central City Hospital, Kakogawa, Japan, ³Kakogawa Central City Hospital, Kobe, Japan, ⁴Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Mepolizumab (MPZ), an anti–interleukin-5 monoclonal antibody, has shown efficacy in reducing glucocorticoid (GC) dosage and sustaining remission in eosinophilic granulomatosis with polyangiitis (EGPA). This…
Abstract Number: 1593 • ACR Convergence 2025
Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients
Blaise Pasquiers¹, Benoit Blanchet², Xavier Puéchal³, Xavier Declèves¹, Pascal Cohen⁴, Claire Goulvestre¹, Marion Casadevall¹, Ines Benhabiles¹, Michel Vidal¹, David Ternant¹, Benjamin Terrier⁵ and Alicja Puszkiel⁶, ¹Hopital Cochin, Paris, France, ²National Referral Centre for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Cochin Hospital, Paris, France, ⁶Cochin Hospital, Paris
Background/Purpose: For the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), rituximab (RTX) may be given as a 4-dose regimen (375 mg/m2 weekly for 4…
Abstract Number: 0840 • ACR Convergence 2025
Shared and Distinct Urinary Proteomic Signatures of Lupus Nephritis and Other Glomerular Diseases
Alessandra Ida Celia¹, Daksh Saksena², CHEN-YU LEE³, Carla Guthridge⁴, Wade DeJager⁵, Rufei Lu⁴, Judith James⁴, Jill Buyon⁶, Michelle Petri⁷, Joel Guthridge⁴, Brad Rovin⁸ and Andrea Fava³, ¹Sapienza University of Rome, Rome, Italy, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Urine collects the byproducts of kidney biology and has emerged as a valuable, noninvasive source of molecular information that reflects intrarenal pathology. In lupus…
Abstract Number: 2508 • ACR Convergence 2025
Patient-Reported Outcomes in ANCA-Associated Vasculitis: Early Findings from a Prospective Real-World Cohort
Colebrooke Johnson¹, Nora Shepherd², David O'Dea¹, Andrew King², Guy Katz¹, Belen Arevalo Molina¹, Zachary Williams³, Madison Negron⁴, Naomi Patel¹ and Sebastian H Unizony⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Nancy, KY, ⁴Harvard Extension School, Medford, MA, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) imposes a high morbidity burden, both from the disease itself and from treatment-related side effects, often compromising patients’ quality of life…
Abstract Number: 1609 • ACR Convergence 2025
A Multicenter Prospective Longitudinal Observational Study To Determine Safety Of Extended Treatment With Rituximab In Maintaining Remission In Patients With ANCA Associated Vasculitis (AAV) – An Interim Analysis
Ravi Kumar U¹, Anoop Chitrabhanu², Ramya Janardana³, Avinash Jain⁴, Nitty Mathews⁵, Rutvi Dave⁵, Prabhu Vasantha Kumar⁶, ashish mathew⁵, john mathew⁵, Prasanna Samuel⁵, Arul Rajamurugan², Vineeta Shobha³ and ruchika goel⁵, ¹Christian Medical college, Vellore, India, Bengaluru, Karnataka, India, ²Madras Medical College, Chennai, India, Chennai, Tamil Nadu, India, ³St. John’s Medical College, Bengaluru , India, Bangalore, Karnataka, India, ⁴SMS Medical College and Hospital, Jaipur, India, JAIPUR, Rajasthan, India, ⁵Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ⁶Christian Medical College, Vellore, Tamil Nadu, India, Vellore, Tamil Nadu, India
Background/Purpose: Rituximab (RTX) has been shown to achieve high remission-induction and sustained maintenance rates across multiple studies and clinical trials in patients with AAV. The…
Abstract Number: 1592 • ACR Convergence 2025
Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Adrien Cottu¹, Irene Mattioli², Xavier Puéchal³, Loic Guillevin⁴, Mathieu Groh⁵, Camille Taillé⁶, Maxime Samson⁷, Pascal Cathébras⁸, Halil Yildiz⁹, Grégory Pugnet¹⁰, Stéphane Jouneau¹¹, Marie-Charlotte Besse¹², François Lifermann¹³, Jean-Philippe Martellosio¹⁴, Laurent Guilleminault¹⁵, Colas Tcherakian¹⁶, Yann Nguyen¹⁷, Claire Demoreuil¹⁸, Philippe Guilpain¹⁹, Giacomo Emmi²⁰ and Benjamin Terrier²¹, ¹Internal medicine departement, Cochin Hospital, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Hôpital Foch, Suresnes, France, ⁶Bichat hospital, APHP, Paris, France, ⁷CHU Dijon Bourgogne, Dijon, France, ⁸Internal medicine department, CHU St-Etienne, Saint-Etienne, France, ⁹Internal medicine department, Saint-Luc, Saint-Luc, France, ¹⁰CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ¹¹Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ¹²Tours University Hospital, ³⁷⁰⁰⁰ tours, Ile-de-France, France, ¹³Internal Medicine, CH de Dax, Dax, France, ¹⁴Internal medicine department, CHU Poitiers, Poitiers, France, ¹⁵CHU Toulouse, Toulouse University, Toulouse, France, ¹⁶Pneumology department, Foch, Suresnes, France, ¹⁷Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁸Internal medicine department, Brest CHU, Brest, France, ¹⁹Internal medicine department, CHU Montpellier, Montpellier, France, ²⁰Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, Trieste, Italy, ²¹Cochin Hospital, Paris, France
Background/Purpose: Glucocorticoid (GC)-dependent asthma and ENT exacerbations may persist in more than half of patients with eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab and benralizumab, monoclonal…
Abstract Number: 0730 • ACR Convergence 2025
Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
Victor Pimentel-Quiroz¹, Alvaro Oyarce-Calderón², Allison Figueroa-Sánchez³, Leonor León-Yaurimucha³, Rocío Gamboa-Cárdenas⁴, Zoila Rodríguez-Bellido⁵, Risto Perich-Campos⁶, Graciela Alarcón⁷ and Manuel Ugarte-Gil⁸, ¹Universidad Científica del Sur, San Isidro, Peru, ²Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA, ⁸Universidad Cientifica del Sur, Lima, Peru
Background/Purpose: It is known that health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) is impaired. Categories of disease activity levels have been…
Abstract Number: 2506 • ACR Convergence 2025
Timing, Management, and Outcomes of Venous Thromboembolic Events in ANCA-Associated Vasculitis: A Retrospective Cohort Study
Bruno Marchetti¹, Michele Iudici², Yann Nguyen³, Pascal Cohen⁴, Loic Guillevin⁴, Xavier Puéchal⁵ and Benjamin Terrier⁶, ¹Department of Internal Medicine, University of Turin, Mauriziano Hospital, Torino, Italy, ²Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, ³Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁶Cochin Hospital, Paris, France
Background/Purpose: ANCA-associated vasculitis (AAV) has been associated with an increased risk of venous thromboembolic events (VTE). However, limited data are available regarding the precise timing,…
Abstract Number: 1608 • ACR Convergence 2025
Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Christian Pagnoux⁸, Ulrich Specks⁹, Benjamin Terrier¹⁰, Lena Börjesson Sjö¹¹, Priya Jain¹², Aadarsh Lal¹³, Sofia Necander¹⁴, Claire Walton¹⁵ and Michael Wechsler¹⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁹Mayo Clinic, Rochester, MN, ¹⁰Cochin Hospital, Paris, France, ¹¹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹³Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹⁴Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁵Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁶Department of Medicine, National Jewish Health, Denver
Background/Purpose: Results from the 1-year double-blind period and first year of the open-label extension (OLE) of the MANDARA trial (NCT04157348) demonstrated that over 60% of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].